| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Stephen Gordon last filed a Form 4 in June 2024, as Chief Financial Officer at TMDX. Stephen Gordon's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Stephen Gordon's trades have earned a middling insider score of 52/100 across 23 rated trades. Over a 12-month horizon, 43.5% of those trades were profitable, with an average 12-month return of -12.3%.
At the last filing, the largest reported position was 21,299 shares of TMDX. The TMDX filings lean toward selling, a net 263,963 shares.
Stephen Gordon has 36 Form 4 filings on record from May 2019 to June 2024, all as Chief Financial Officer at TransMedics Group (TMDX), 2019–2024.
The 79 reported transactions were 33 open-market sales, 32 option exercises, 6 other transactions and 5 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 28 sales worth about $16.9M.
The largest open-market sale was 20,000 shares of TMDX at an average $141.40 on May 29, 2024, about $2.8M. Twelve months later TMDX was down 10%.
6 of the 10 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 4 were not.
Shares as reported in the last Form 4 for each company; the most recent is from June 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 2,060 | $135.93 | $280,015.80 | -8.8% | +19.3% | -3.7% | |
| May 29, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE | 20,000 | $141.40 | $2,828,024.70 | -48.4% | +23.8% | -10.3% | |
| May 6, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 15,000 | $128.00 | $1,920,000.00 | -39.2% | +11.9% | -29.6% | |
| Apr 1, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 15,000 | $74.01 | $1,110,150.00 | -39.2% | +104.5% | -7.0% | |
| Mar 8, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sell | 1,903 | $87.63 | $166,759.89 | -7.6% | +58.8% | -19.5% | |
| Mar 4, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 15,000 | $82.80 | $1,242,000.00 | -37.3% | +53.6% | -20.5% | |
| Feb 1, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 15,000 | $85.45 | $1,281,750.00 | -53.4% | +32.8% | -23.7% | |
| Jan 2, 2024 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE10b5-1 | 15,000 | $77.07 | $1,156,050.00 | -53.4% | -4.4% | -13.4% | |
| Oct 2, 2023 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE | 5,000 | $54.22 | $271,100.00 | -21.0% | +45.5% | +174.4% | |
| May 1, 2023 | TMDX Transmedics Group, Inc. | Chief Financial Officer | Sale+OE | 5,000 | $79.05 | $395,250.00 | -21.0% | +19.7% | +20.9% |